Inogen Inc (NASDAQ:INGN) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: October 5, 2016
Zacks Investment Research has downgraded Inogen Inc (NASDAQ:INGN) to Hold in a statement released on 10/05/2016.
On 10/04/2016, Zacks Investment Research released a statement on Inogen Inc (NASDAQ:INGN) upped the target price from $0.00 to $67.00 that suggested an upside of 0.13%.
Having a price of $60.87, Inogen Inc (NASDAQ:INGN) traded 2.10% higher on the day. With the last close up 18.40% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Inogen Inc has recorded a 50-day average of $58.62 and a two hundred day average of $51.24. Volume of trade was down over the average, with 94,625 shares of INGN changing hands under the typical 192,260
With a total market value of $0, Inogen Inc has price-earnings ratio of 89.22 with a one year low of $28.81 and a one year high of $61.87 .
A total of 5 analysts have released a report on Inogen Inc. 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $54.20.
Brief Synopsis About Inogen Inc (NASDAQ:INGN)
Inogen, Inc. is a medical technology company. The Company is engaged in developing, manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company's Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device weighing approximately 4.8 or seven pounds. Its Inogen One G2 and Inogen One G3 have approximately five and 4.5 hours of battery life, respectively, with a single battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. The Inogen At Home stationary oxygen concentrator allows it to access the non-ambulatory patient market and serves as a backup to its Inogen One system for ambulatory patients. The Company sells its products to home medical equipment providers in the United States and in foreign countries.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.